Key Findings:  In patients with chronic kidney disease (CKD) the lipid-lowering drug fluvastatin was renoprotective as evidenced by reduced levels of urinary albumin excretion (UAE) and liver-type fatty acid binding protein (L-FABP).
Type of Study:  Clinical Trial
Study Sample Size:  43
Study Result:  Positive
Research Location(s):  Japan
Year of Pub:  2011
Cannabinoids Studied:  Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source:  Not Applicable
Route of Administration:  Endogenous
Citation:  Inoue T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Intern Med. 2011; 50:1273-8. doi: 10.2169/internalmedicine.50.4059
Authors:  Inoue T, Ikeda H, Nakamura T, Abe S, Taguchi I, Kikuchi M, Toyoda S, Miyazono M, Kishi T, Sanai T, Node K